BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//talks.cam.ac.uk//v3//EN
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:19700329T010000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:19701025T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
CATEGORIES:Electrical Engineering
SUMMARY:Investigating the immune interactions of liposomes
  - unravelling direct and indirect effects on comp
 lex systems. - Dr Neill Liptrott\, Lecturer in Pha
 rmacology at the University of Liverpool
DTSTART;TZID=Europe/London:20210422T160000
DTEND;TZID=Europe/London:20210422T170000
UID:TALK159448AThttp://talks.cam.ac.uk
URL:http://talks.cam.ac.uk/talk/index/159448
DESCRIPTION:Neill’s research investigates the biological inter
 actions of conventional and nanotechnology-enabled
  medicines and therapeutics\; encompassing assessm
 ent of the biocompatibility\, immuomodulatory pote
 ntial and risk of these novel therapeutic strategi
 es to aid in the preclinical evaluation of new mat
 erials as well enabling future rational design of 
 nanomaterials and therapies.  Neill has worked at 
 the National Institutes of Health (NIH) National C
 ancer Institute’s (NCI) Nanotechnology Characteris
 ation Laboratory (NCL) based in Frederick\, Maryla
 nd\, USA and is a Lecturer in the Department of Ph
 armacology and Therapeutics where he heads a numbe
 r of advanced therapeutics/materials immunocompati
 bility research programmes. Additionally\, Neill i
 s a member of the Core Expert Team (CET) and Assay
  Group leader (Immunotoxicity and Haematotoxicity)
  for the European Nanomedicine Characterisation La
 boratory (EUNCL). Although our work spans many dif
 ferent advanced materials and complex medicines\, 
 this talk will detail some of our work on liposome
 s\, given the recent resurgence due to their appli
 cation in the COVID-19 vaccination programmes. In 
 the context of carriers for small molecules and nu
 cleic acids\, we will discuss known interactions w
 ith the immune system that may affect their biocom
 patibility or reveal novel properties that give a 
 therapeutic advantage. In particular\, we will dis
 cuss our efforts to link together systems that may
  interact to bring about unwanted effects.
LOCATION:Meeting ID: 837 8058 8985 Passcode: 428653
CONTACT:Kirsty Shepherd
END:VEVENT
END:VCALENDAR